Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada
-
-
-
-
-
Praha, Czechia
-
-
-
-
-
Paris, France
-
-
-
-
-
Munich, Germany
-
-
-
-
-
Seoul, Korea, Republic of
-
-
-
-
-
Manila, Philippines
-
-
-
-
-
Poznan, Poland
-
-
-
-
California
-
Newport Beach, California, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical enlargement of the prostate gland
- Body weight ≥ 50 kg or 110 lbs
Exclusion Criteria:
- History of chronic prostatitis
- History of two or more urinary tract infections in the past year or one in the last 6 months
- History of bladder stones
- History of previous prostate surgery
- History of bladder cancer or prostate cancer
- Any previous or current usage of botulinum toxin therapy of any serotype for any urological condition
- Botulinum toxin therapy of any serotype for any non-urological condition or usage (e.g., cosmetic) during the previous 12 weeks prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: botulinum toxin Type A
botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
|
botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
Other Names:
|
|
Placebo Comparator: Placebo (Normal saline)
Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
|
Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Week 12
Time Frame: Baseline, Week 12
|
IPSS is a disease-specific outcome measure based on the American Urological Association Symptom Index.
The questionnaire consisted of seven items.
The patient evaluated their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks.
The total symptom score ranged from 0 (no symptoms) to 35 (most severe symptoms).
A negative change from Baseline indicated improvement.
|
Baseline, Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in the Total International Prostate Symptom Score (IPSS)
Time Frame: Baseline, Week 6, Week 24
|
IPSS is a disease-specific outcome measure based on the American Urological Association Symptom Index.
The questionnaire consisted of seven items.
The patient evaluated their urinary symptoms (incomplete emptying, frequency, hesitancy, urgency, weak stream, straining, and nocturia) during the previous 4 weeks.
The total symptom score ranged from 0 (no symptoms) to 35 (most severe symptoms).
A negative change from Baseline indicated improvement.
|
Baseline, Week 6, Week 24
|
|
Change From Baseline in Peak Urine Flow Rate
Time Frame: Baseline, Weeks 6, 12 and 24
|
Urinary flow was determined by uroflowmetry measured in milliliters/second (mL/sec).
An increase from Baseline indicated improvement.
|
Baseline, Weeks 6, 12 and 24
|
|
Duration of Effect
Time Frame: 24 Weeks
|
Duration of effect was calculated from the time of the first follow-up visit with a ≥ 4-point reduction from Baseline in IPSS to the next visit when the IPSS change from Baseline was < 4-points.
|
24 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
Other Study ID Numbers
- 191622-100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.